Trial Profile

A Phase 2a, randomized, placebo-controlled, dose-ranging study to evaluate the safety and efficacy of PTC518 in subjects with Huntington's disease

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 13 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Votoplam (Primary)
Indications Huntington's disease
Focus Adverse reactions; Therapeutic Use
Acronyms PIVOT-HD
Sponsors PTC Therapeutics

Most Recent Events

06 May 2025 According to a PTC Therapeutics media release, company plans to complete additional analyses and discuss next development and regulatory steps, including potential for accelerated approval
05 May 2025 Primary endpoint has been met. (Change From Baseline in Blood Total Huntingtin Protein (tHTT) at Month 3)
05 May 2025 Results presented in the PTC Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com